Hugo (robot surgeon)

2022

Robotic gynecologist surgery on a human

On December 15, 2022, Medtronic announced the admission of the first patient to the Expand URO U.S. clinical trial for the Hugo surgical robot.

The procedure was performed by Dr. Michael Abern of Duke University Hospital. He used Hugo's Robot Assisted Surgery (RAS) system to perform a robot assisted prostatectomy procedure.

Robot gynecologist Medtronic began performing operations

{{quote 'This is an exciting moment! Robot assisted surgery provides many advantages in my specialty - urology, and I am proud to conduct the first USA in a clinical trial of Medtronic's RAS Hugo system, "said Dr. Michael Abern. }} Medtronic intends to use the Hugo system in the study for a range of urological surgical procedures. This includes radical prostatectomy, radical cystectomy, and nephrectomy (partial or radical) at sites in the United States.

Up to 122 patients will be enrolled in the study under the FDA's Investigational Device Authorization (IDE). It includes six facilities throughout the United States. Dr. James Porter, a urologist surgeon at the Swedish Medical Center in Seattle, serves as principal investigator. He expects to carry out the first operations as part of the study this month.

Hugo combines with Medtronic's Touch Surgery Enterprise system to provide an intelligent, digital surgical experience. It combines wrist tools and 3D visualization in one platform. Touch Surgery Enterprise, Medtronic's cloud-based solution for capturing and managing surgical video, helps offer a multi-quadrant platform designed for a wide range of soft tissue treatments.

The system received European approval in October 2021, but in the US Hugo remains a research vehicle for December 2022 as clinical trials continue.^[1]

Start deliveries worldwide

On October 19, 2022, the company Medtronic announced global sales of the Hugo robotic surgical system. The company received CE mark approval for general surgery applications, Ministry license health care Canada for general laparoscopic surgery applications, and Ministry of Health, Labor and Welfare approval for urological surgery and gynecological laparoscopy applications in. Japan

The new readings and permits open up access to Hugo robot assisted surgery in Europe, North America and Asia, expanding the benefits of minimally invasive surgery. Robot-assisted procedures have fewer complications, shorter hospital stays and a faster return to normal patient activities. General surgery, gynecology and urology account for more than 80% of all robot assisted surgical procedures performed in the world, and general surgery is the fastest growing segment in robotic surgery, according to Medtronic.

Medtronic began supplying a robot surgeon around the world

{{quote 'Obtaining these important approvals paves the way for our expansion into key robotics markets! The Hugo system was designed to remove barriers to the adoption of robotic surgery, and these approvals are significant steps in ensuring the benefits of minimally invasive surgery for more patients in more places around the world, said Mike Marinaro, senior vice president and president of Medtronic's surgical robotics division. }} Hugo uses Touch Surgery Enterprise, a cloud-based solution for capturing and managing surgical video, to offer an intelligent, digital surgical experience. The device has wrist tools, 3D visualization and special support teams that specialize in optimizing robotics programs, maintenance and training.^[2]

2021

Start of sales in Europe

In mid-October 2021, Medtronic secured European approval for its Hugo surgical robot, paving the way for the system's continental debut in many countries. Deliveries of equipment to clinics have begun.

Despite much hype around robotic surgery, including orthopedic systems from Stryker, Zimmer Biomet and Johnson and Johnson, a small percentage of operations are actually performed with this technology. Only about 3% of operations are performed using robots, according to Medtronic. The medical technology company claims that the cost played a role in limiting the implementation, because the cost of some systems can reach $1 million and hospitals lease systems, and do not buy them immediately.

The first robot surgeon Medtronic Hugo began selling in Euros

]]

Medtronic said the Hugo system was designed to remove historical barriers to cost and use that have held back the adoption of robotic surgery for two decades. However, the company did not provide information on the cost of its system in the release.

This day has long come not only for Medtronic, but also for surgeons and hospital leaders who have become our partners on this journey to provide the benefits of robotic surgery to more patients around the world, said Megan Rosengarten, president of Medtronic's surgical robotics division.

The robotic platform, which consists of modular surgical manipulators on wheeled carts, also tested its first operation in the Asia-Pacific region through prostatectomy in Chennai, India. All of the company's systems are linked to a global patient registry that tracks outcomes and feeds that data back to the platform.

Now To Europe , as a sign of CE, it extends to urological and gynecological procedures, such as hysterectomy and removal of uterine fibroids. Medtronic says the green light gives access to about half of all robotic operations performed for October 13, 2021. The CE mark is largely in line with a timeline first set by the company in late 2019 that targets Europe before seeking regulatory approval from the Food and Drug Administration (FDA FDA USA) in and in broader indications for soft tissue surgery.^[3]

Using a Robot for Gynecological Operations

At the end of July 2021, Medtronic announced the first gynecological operations using the RAS Hugo robotic surgery system. The new system was successfully used during six procedures, including hysterectomy and myomectomy and performed at Pacifica Salud Hospital in Panama City (Panama). Read more here.

2019: Announcement

In late September 2019, Medtronic unveiled Hugo, a robotic surgical platform that has been in development for years. The company promises that the new robot surgeon with a modular configuration system will reduce the cost of many operations and expand the scope of surgical robotics.

According to the company, its robotic system was developed with the participation of more than 100 of the best surgeons in the United States. Medtronic trains 9,000 surgeons worldwide each year to work with their surgical instruments and invests tirelessly in their development. In the first quarter of 2021, Medtronic plans to apply for registration of a new robotic system in Europe and the United States. Clinical studies of the robot surgeon in the global market will begin at the end of 2019.

Medtronic unveils Hugo robotic surgical platform

The company expects robotic surgery to develop intensively in the coming years, but so far this market is extremely undervalued, which is associated with the high cost of each procedure, because on average the installed system is used only once a day. Therefore, the company introduced a modular robot surgeon.

The module platform consists of an open surgeon console, imaging system and robotic arms with surgical instruments. At the same time, the imaging system and many tools, such as staplers, can be used in both robotic and laparoscopic procedures, and various components can be updated as the hospital is able. The company hopes the new modular system will attract new buyers who could not purchase the robotic platform earlier. However, analysts note that everything will depend on the real effectiveness of the system that it must demonstrate in clinical trials.^[4]

Notes